Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02389543Phase 2Withdrawn
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Maximum Tolerated Dose at 12 months and Overall Response Rate at 12 months. Planned start Jul 2015; status: withdrawn.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02389543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389543.